Detalhe da pesquisa
1.
Opioid metabolism and drug-drug interaction in cancer.
Oncologist
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38780124
2.
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.
BMC Cancer
; 24(1): 31, 2024 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38172718
3.
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
J Transl Med
; 20(1): 371, 2022 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35974365
4.
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence.
J Med Virol
; 94(2): 491-498, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31002743
5.
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Pharmacol Res
; 181: 106290, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35680010
6.
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Cancer Immunol Immunother
; 70(6): 1667-1678, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33315149
7.
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Pharmacogenomics J
; 21(2): 233-242, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462346
8.
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
Pharmacol Res
; 167: 105537, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33684510
9.
Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives.
Pharmacol Res
; 169: 105643, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33940185
10.
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Pharmacol Res
; 163: 105241, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33049397
11.
Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?
Pharmacol Res
; 156: 104786, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32278037
12.
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.
Breast Cancer Res Treat
; 176(3): 483-494, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31065872
13.
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Breast Cancer Res Treat
; 178(1): 57-62, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31346846
14.
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Pharmacogenomics J
; 19(6): 556-563, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30723313
15.
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells.
Stem Cells
; 36(5): 633-640, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29352734
16.
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.
BMC Cancer
; 19(1): 410, 2019 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31039766
17.
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Hematol Oncol
; 37(1): 3-14, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30187496
18.
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer.
BJU Int
; 124(4): 693-700, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31055861
19.
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy.
Int J Mol Sci
; 20(16)2019 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31416192
20.
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.
Br J Cancer
; 119(10): 1252-1258, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30397287